CSPIA
ACAD icon

Cary Street Partners Investment Advisory’s Acadia Pharmaceuticals ACAD Stock Holding History

Cary Street Partners Investment Advisory’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-10,530
Closed -$434K – 356
2020
Q3 		$434K Buy
+10,530
New +$455K 0.09% 189

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Cary Street Partners Investment Advisory's ACAD Position: Q4 2020 in Review

Cary Street Partners Investment Advisory sold out of Acadia Pharmaceuticals (ACAD) in Q4 2020, closing a stake of 10,530 shares — an estimated $434K sold.

Cary Street Partners Investment Advisory first reported a position in ACAD in Q3 2020 and held it in 1 quarter. The position peaked at $434K in Q3 2020. 308 funds tracked by Wall St. Rank hold ACAD as of Q4 2020.

  • Cary Street Partners Investment Advisory reported no remaining Acadia Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Cary Street Partners Investment Advisory sold 10,530 Acadia Pharmaceuticals shares in Q4 2020, an estimated $434K.
  • Cary Street Partners Investment Advisory first reported a position in Acadia Pharmaceuticals in Q3 2020 and held it in 1 quarter.
  • Cary Street Partners Investment Advisory's Acadia Pharmaceuticals position peaked at $434K in Q3 2020.
  • 308 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2020.

Based on Cary Street Partners Investment Advisory's 13F filing for Q4 2020, filed 12 Feb 2021.